Month Year
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
Month Year
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
-
Apr 26, 2021- New imaging platform merges optical coherence tomography (OCT) with the power of automation using artificial intelligence (AI)- Ultreon 1.0 Software helps physicians automatically detect and quantify blood vessel characteristics, giving them better insights for optimal patient treatment- Platform offers advanced imaging features when combined with the Dragonfly OpStar™ imaging catheter used to access complex anatomy
Apr 20, 2021- Sales growth of 35.3 percent; organic sales growth of 32.9 percent- GAAP diluted EPS growth from continuing operations of 233.3 percent; adjusted diluted EPS growth of 103.1 percent- All four major businesses achieved strong sales growth in the quarter- Projected full-year EPS remains unchanged; reflects growth of more than 35 percent-
Apr 19, 2021- BinaxNOW is the most studied and widely available rapid antigen test in the U.S. and initially will be available at CVS Pharmacy, Walgreens and Walmart without a prescription- Abbott to manufacture tens of millions of BinaxNOW Self Tests per month and can scale capacity upward based on demand- The BinaxNOW Self Test will be sold in 2-count packs for an MSRP of $23.99, making it the most affordable over-the-counter (OTC) COVID-19 rapid test available in the U.S.
Apr 12, 2021- Abbott, Eliud Kipchoge and the NN Running Team collaborate in a partnership to track glucose levels during training and marathons- Kipchoge and NN Running Team members will wear Abbott's Libre Sense Glucose Sport Biosensor in upcoming competition at the NN Mission Marathon, the fastest way to the Tokyo Games- Built upon the company's world-leading continuous glucose monitoring technology,[i] Abbott's Libre Sense is the world's first glucose biosensor[ii] designed for athletes to help sports performance- Apr 8, 2021- New enhancements to first-of-its-kind device uniquely developed for the difficult-to-treat tricuspid valve- Next-generation therapy offers enhanced leaflet grasping feature and new clip sizes to fit each patient's complex tricuspid valve anatomy- TriClip G4 makes treatment more customizable, expanding options for physicians seeking innovative transcatheter structural heart solutions